
2008 Supplement
MORTALITY IN RHEUMATIC DISEASES
Clinical and Experimental Rheumatology

Guest editors
T. Sokka, T. Pincus



Sponsored by the
NYU Post-Graduate Medical School

Supported by educational grants from:
Abbott Laboratories; Amgen & Wyeth Pharmaceuticals;
Bristol-Myers Squibb, Inc.; Centocor, Inc.; Genentech/Biogen IDEC; Pfizer, Inc.

Release date: December 15, 2008
Expiration date: December 14, 2009



NYU Post-Graduate Medical School

DIVISION OF CONTINUING MEDICAL EDUCATION

Clinical and Experimental Rheumatology

Target Audience

This activity is designed for rheumatologists.

Statement of Need

Mortality in Rheumatic Diseases is a much-neglected area, which could give an improved visibility to these diseases and sense of urgency concerning treatment, as well as support for further research for rheumatic diseases. In many patients, diseases such as vasculitis, scleroderma, systemic lupus erythematosus, polymyositis, etc. have a natural history disease that includes as severe a risk of early death as most forms of cancer and cardiovascular disease. However, rheumatic diseases are not associated with a similar aura of severity as neoplastic and malignant diseases. Rheumatologists, rheumatology fellows, internists and family practitioners need to understand the severity of rheumatic diseases by promoting knowledge of increased risk of premature death.

Educational Objectives

- describe the mortality risks posed by many rheumatic diseases, specifically, ankylosing spondylitis, scleroderma, systemic lupus erythematosus, and vasculitis.
- discuss effective treatments for rheumatic diseases and the importance of early and effective intervention.

Accreditation Statement

The NYU Post-Graduate Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The NYU Post-Graduate Medical School designates this educational activity for a maximum of 9.0 *AMA PRA Category 1 Credits™*. Physicians should only claim credits commensurate with the extent of their participation in the activity.

Method of Participation

To receive up to 9.0 CME credits, read this supplement, which should take 9.0 hours of your time, complete the post-test with a minimum passing grade of 70%, complete the evaluation, and submit to the NYU Post-Graduate Medical School (instructions enclosed).

This activity is valid for credit from December 15, 2008 through December 14, 2009.

Faculty Credentials

Stefano Bombardieri, MD
Professor of Rheumatology
Rheumatic Disease Unit
Department of Internal Medicine
University of Pisa
Pisa, Italy

Jürgen Braun, MD
Professor of Medicine and Rheumatology
Rheumazentrum-Ruhrgebiet
St.Josefs-Krankenhaus
Herne, Germany

Hyon K. Choi, MD, DrPH
Professor of Rheumatology
Division of Rheumatology
Department of Medicine
University of British Columbia
Arthritis Research Centre of Canada
Vancouver, BC, Canada

Dafna D. Gladman, MD, FRCPC
Professor of Medicine, University of Toronto
Senior Scientist, Toronto Western Research Institute
Deputy Director, Centre for Prognosis Studies in The Rheumatic Diseases
Director, Psoriatic Arthritis Program
Toronto, ON, Canada

Marc C. Hochberg, MD, MPH
Professor of Medicine and Epidemiology and Preventive Medicine
Head, Division of Rheumatology and Clinical Immunology
University of Maryland School of Medicine
Baltimore, Maryland, USA

John P.A. Ioannidis, MD
Professor and Chairman, Department of Hygiene and Epidemiology
University of Ioannina School of Medicine
Ioannina, Greece
and Institute for Clinical Research and Health Policy Studies
Department of Medicine
Tufts Medical Center
Boston, MA, USA

Ingrid E. Lundberg MD, PhD
Professor, Rheumatology Unit
Department of Medicine
Karolinska University Hospital
Stockholm, Sweden

Raashid Luqmani, DM, FRCP
Senior Lecturer
Botnar Research Centre
University of Oxford
Oxford, UK

Haralampos M. Moutsopoulos, MD
Professor and Head, Department of Pathophysiology,
Medical School
National University of Athens
Athens, Greece

Michelle A. Petri, MD, MPH

Professor of Medicine, Director of Lupus Center,
Division of Rheumatology, Department of Medicine,
Johns Hopkins University School of Medicine
Baltimore, MD, USA

Theodore Pincus, MD

Clinical Professor of Medicine
New York University School of Medicine
Director, Outcomes Research
Division of Rheumatology
NYU Hospital for Joint Diseases
New York, NY, USA

Kenneth G. Saag, MD, MSc

Professor of Medicine and Epidemiology
Director, Center for Education and Research on
Therapeutics (CERTs) of Musculoskeletal Disorders
Division of Clinical Immunology and Rheumatology
University of Alabama at Birmingham
Birmingham, AL, USA

Tuulikki Sokka, MD, PhD

Consultant in Rheumatology, Jyväskylä Central Hospital
Senior Researcher, Medcare Oy
Jyväskylä, Finland

C. Michael Stein, MD

Professor of Rheumatology and Pharmacology
Department of Medicine, Divisions of Rheumatology and
Clinical Pharmacology Vanderbilt University
Nashville, TN

Hasan Yazici, MD

Professor of Medicine
Division of Rheumatology
Cerrahpaşa Medical Faculty
University of Istanbul
Istanbul, Turkey

Jane Zochling, PhD

Research Fellow and Rheumatologist Menzies Research Institute
Hobart, Australia

Disclosure Statement

The NYU Post-Graduate Medical School adheres to ACCME Essential Areas and policies, including the Standards for Commercial Support, regarding industry support of continuing medical education. In order to resolve any identified conflicts of interest, disclosure information is provided during the planning process to ensure resolution of any identified conflicts. Disclosure of faculty and commercial relationships as well as the discussion of unlabeled or unapproved use of any drug, device or procedure by the faculty is listed below.

Stefano Bombardieri, MD reports no relevant financial relationships.

Jürgen Braun, MD serves as a consultant to and receives research support from Abbott Laboratories, Bristol-Myers Squibb, Inc., Centocor, Inc., Pfizer, Inc., Roche Laboratories, Schering-Plough Corp., and Wyeth Pharmaceuticals.

Hyon K. Choi, MD, DrPH serves as a consultant to TAP Pharmaceutical Products, Inc.

Dafna D. Gladman, MD serves as a consultant to Abbott Laboratories, Amgen, Centocor, Inc., Schering-Plough Corp., and Wyeth Pharmaceuticals.

Marc C. Hochberg, MD, MPH receives royalties from Elsevier Publishing, Inc., and serves as a consultant to Amgen, BioIberica S.A., Bristol-Myers Squibb, Inc. CombinatoRx, Merck & Co. Inc., NicOx S.A., and Roche Laboratories, Inc. Dr. Hochberg serves as a member of a Data Safety and Monitoring Board (DSMB) for Novartis Pharma AG.

John P.A. Ioannidis, MD reports no relevant financial relationships.

Ingrid E. Lundberg MD, PhD reports no relevant financial relationships.

Raashid Luqmani, DM, FRCP reports no relevant financial relationships. Dr. Luqmani's presentation will include discussion of the unlabeled use of cyclophosphamide and methotrexate to treat vasculitis.

Haralampos M. Moutsopoulos, MD receives royalties from Abbott Laboratories and Roche Laboratories, and serves as a consultant to Abbott Laboratories and Bristol-Myers Squibb, Inc.

Michelle A. Petri, MD, MPH receives research support from Aspreva Pharmaceuticals, Human Genome Sciences, Inc., Genentech, MedImmune, Inc., and UCB, Inc.

Theodore Pincus, MD serves as a consultant to Abbott Laboratories, Amgen, Bristol-Myers Squibb, Inc., Centocor, Inc. and Pfizer, Inc., and receives research support from Amgen and Bristol-Myers Squibb, Inc.

Kenneth G. Saag, MD, MS serves as a consultant to Amgen, Eli Lilly & Co., Merck & Co., Novartis Pharmaceuticals Corp., and Roche Laboratories. Dr. Saag is a member of the Speakers' Bureaus of Merck & Co., and Novartis Pharmaceuticals Corp. Dr. Saag also receives research support from Amgen, Glaxo-SmithKline, Eli Lilly & Co., Merck & Co., Novartis Pharmaceuticals Corp., Roche Laboratories, Sanofi-Aventis US, Inc. and TAP Pharmaceutical Products, Inc.

Tuulikki Sokka, MD, PhD serves as a consultant to Abbott Laboratories, Sanofi-Aventis, UCB Pharma and Wyeth Pharmaceuticals.

C. Michael Stein, MD reports no relevant financial relationships. Dr. Stein's presentation will include discussion of experimental use of tocilizumab to treat rheumatoid arthritis.

Hasan Yazici, MD reports no relevant financial relationships.

Jane Zochling, MD reports no relevant financial relationships.

The independent reviewer of this activity reports no relevant financial relationships.

Copyright © 2008, The NYU Post-Graduate Medical School. All rights reserved.